Synthesis and Biological Evaluation of Heterocyclic Ring-Fused 20( S )-Protopanaxadiol Derivatives as Potent Antiosteoporosis Agents
Journal of Medicinal Chemistry · 14.09.2023 · 66 (17) · 11965-11984
DOI: 10.1021/acs.jmedchem.3c00601 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 19.08.2023. Verfasst von Shuan-Jing Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China No…. Hauptthemen laut MEDLINE: Adenosine Triphosphatases, Osteoporosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China, School of Medicine, Shanghai Jiaotong University.
Abstract (Originalsprache)
A series of heterocyclic ring-fused derivatives of 20(S)-protopanaxadiol (PPD) were synthesized and evaluated for their inhibitory effects on RANKL-induced osteoclastogenesis. Among these compounds, 33 (SH491, IC50 = 11.8 nM) showed the highest potency with 100% inhibition at 0.1 μM and 44.4% inhibition at an even lower concentration of 0.01 μM, which was much more potent than the lead compound PPD (IC50 = 10.3 μM). Cytotoxicity tests indicated that the inhibitory effect of these compounds on RANKL-induced osteoclast differentiation was not due to their cytotoxicity. Interestingly, SH491 also exhibited a notable impact on the osteoblastogenesis of MC3T3-E1 preosteoblasts. Mechanistic studies revealed that SH491 inhibits the expression of osteoclastogenesis-related marker genes and proteins, including TRAP, CTSK, MMP-9, and ATPase v0d2. In vivo, SH491 could dramatically decrease the ovariectomy-induced osteoclast activity and relieve osteoporosis obviously. Thus, these PPD derivatives could be served as promising leads for the development of novel antiosteoporosis agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.
- Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of…
ORCID-Profile: Xing Xu, Min Jiang, Wen-Wei Qiu
Förderung
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
- School of Medicine, Shanghai Jiaotong University
Zitieren
APA
Wang, S. J., Zhang, J., Zhang, J. Z., Ning, R. N., Li, C. C., Xu, X., Jiang, M., & Qiu, W. W. (2023). Synthesis and Biological Evaluation of Heterocyclic Ring-Fused 20( S )-Protopanaxadiol Derivatives as Potent Antiosteoporosis Agents. Journal of Medicinal Chemistry, 66(17), 11965-11984. https://doi.org/10.1021/acs.jmedchem.3c00601
Vancouver
Wang SJ, Zhang J, Zhang JZ, Ning RN, Li CC, Xu X, et al. Synthesis and Biological Evaluation of Heterocyclic Ring-Fused 20( S )-Protopanaxadiol Derivatives as Potent Antiosteoporosis Agents. Journal of Medicinal Chemistry. 2023;66(17):11965-11984. doi:10.1021/acs.jmedchem.3c00601
BibTeX
@article{Wang2023,
author = {Wang, Shuan-Jing and Zhang, Jiahui and Zhang, Jing-Zan and Ning, Ruo-Nan and Li, Chen-Chen and Xu, Xing and Jiang, Min and Qiu, Wen-Wei},
title = {Synthesis and Biological Evaluation of Heterocyclic Ring-Fused 20( S )-Protopanaxadiol Derivatives as Potent Antiosteoporosis Agents},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {17},
pages = {11965--11984},
doi = {10.1021/acs.jmedchem.3c00601}
}
EUVIMED